Teitsma XM, et al. - In this study, researchers assess the impact of initiation of tocilizumab, with or without MTX, compared with MTX alone on patient-reported outcomes (PROs), in DMARD-naïve patients with early rheumatoid arthritis (RA). Initiation of treat-to-target tocilizumab therapy resulted in significantly improved PROs, particularly within the first 24 weeks, when compared with initiation of MTX therapy. Also on the patients' level, initiating tocilizumab may be considered as a valuable strategy in DMARD-naïve patients with early RA.